Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Pylypenko, H."'
Autor:
Sirko, A., Pylypenko, H.
Publikováno v:
In Brain and Spine 2021 1 Supplement 2
Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in the Phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::6d55190c74da78bac33deffe602fea08
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076477
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076477
In the phase 3 BOSTON study, patients with multiple myeloma (MM) after 1–3 prior regimens were randomized to once-weekly selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly bortezomib-dexamethasone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::6642cfc1f6edb7f253224e66314cecfb
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3101997
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3101997
Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::79e7cdd57698b95815089a4a208b9b9c
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102354
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102354
Publikováno v:
Запорожский медицинский журнал; Том 22 № 1 (2020)
Zaporozhye Medical Journal; Vol. 22 No. 1 (2020)
Zaporozhye Medical Journal; Vol. 22 No. 1 (2020)
The present study aimed to summarize the literature data about wounds to the dural venous sinus (DVS) and validating the importance of surgery in a series of clinical observations in patients with craniocerebral gunshot wound (CGW) sustained in battl
Background: Selinexor combined with dexamethasone has shown activity in patients with heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral selinexor with bortezomib (a proteasome inhibitor) and dexamethasone induced hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::9573e9ba32bf588481caf75108acdf88
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103590
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103590
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Scientific Bulletin of National Mining University; 2021, Issue 6, p170-176, 7p
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::7d278515513371dfaf3993194805014e
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077418
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077418
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.